Guanhao Biotech Co Ltd Total Assets
Guanhao Biotech Co Ltd total assets. Based on the latest financial reports, Guanhao Biotech Co Ltd (300238) holds total assets worth CN¥787.22 Million CNY (≈ $115.20 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is Guanhao Biotech Co Ltd worth for the company's overall valuation and market capitalisation.
Total Assets of Guanhao Biotech Co Ltd (2007–2025)
Total assets of Guanhao Biotech Co Ltd from 2007 to 2025. This chart illustrates how Guanhao Biotech Co Ltd's total assets have evolved over time, based on quarterly financial data. See Guanhao Biotech Co Ltd (300238) stock price for real-time trading data and today's change.
Guanhao Biotech Co Ltd - Asset Composition Analysis
Guanhao Biotech Co Ltd Total Assets Breakdown (December 2025)
Guanhao Biotech Co Ltd total assets breakdown as of December 2025. Guanhao Biotech Co Ltd's total assets of CN¥787.22 Million consist of 40.4% current assets and 59.6% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 19.9% |
| Accounts Receivable | CN¥78.90 Million | 9.8% |
| Inventory | CN¥77.71 Million | 9.6% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥103.04 Million | 12.8% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2007–2025)
This chart illustrates how Guanhao Biotech Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore how liquid is Guanhao Biotech Co Ltd's working capital to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Guanhao Biotech Co Ltd's current assets represent 40.4% of total assets in 2025, a decrease from 73.0% in 2007.
- Cash Position: Cash and equivalents constituted 19.9% of total assets in 2025, down from 52.1% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 12.0% of total assets, an increase from 11.0% in 2007.
- Asset Diversification: The largest asset category is intangible assets at 12.8% of total assets.
Guanhao Biotech Co Ltd Competitors by Total Assets
Key competitors of Guanhao Biotech Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Guanhao Biotech Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.00 | 1.94 | 1.59 |
| Quick Ratio | 1.54 | 1.43 | 1.15 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥154.24 Million | CN¥136.48 Million | CN¥171.51 Million |
Guanhao Biotech Co Ltd - Advanced Valuation Insights
This section examines the relationship between Guanhao Biotech Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.55 |
| Latest Market Cap to Assets Ratio | 0.50 |
| Asset Growth Rate (YoY) | 6.9% |
| Total Assets | CN¥806.53 Million |
| Market Capitalization | $399.65 Million USD |
Valuation Analysis
Below Book Valuation: The market values Guanhao Biotech Co Ltd's assets below their book value (0.50x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Guanhao Biotech Co Ltd's assets grew by 6.9% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Guanhao Biotech Co Ltd (2007–2025)
The table below shows the annual total assets of Guanhao Biotech Co Ltd from 2007 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥806.53 Million ≈ $118.02 Million |
+6.91% |
| 2024-12-31 | CN¥754.40 Million ≈ $110.39 Million |
+11.17% |
| 2023-12-31 | CN¥678.59 Million ≈ $99.30 Million |
+1.25% |
| 2022-12-31 | CN¥670.21 Million ≈ $98.07 Million |
-39.00% |
| 2021-12-31 | CN¥1.10 Billion ≈ $160.78 Million |
-3.17% |
| 2020-12-31 | CN¥1.13 Billion ≈ $166.05 Million |
-1.27% |
| 2019-12-31 | CN¥1.15 Billion ≈ $168.19 Million |
-29.88% |
| 2018-12-31 | CN¥1.64 Billion ≈ $239.85 Million |
-4.60% |
| 2017-12-31 | CN¥1.72 Billion ≈ $251.42 Million |
+1.77% |
| 2016-12-31 | CN¥1.69 Billion ≈ $247.05 Million |
+109.20% |
| 2015-12-31 | CN¥807.02 Million ≈ $118.09 Million |
+30.26% |
| 2014-12-31 | CN¥619.54 Million ≈ $90.66 Million |
+8.21% |
| 2013-12-31 | CN¥572.52 Million ≈ $83.78 Million |
+5.63% |
| 2012-12-31 | CN¥541.99 Million ≈ $79.31 Million |
+9.26% |
| 2011-12-31 | CN¥496.06 Million ≈ $72.59 Million |
+110.18% |
| 2010-12-31 | CN¥236.02 Million ≈ $34.54 Million |
+92.99% |
| 2009-12-31 | CN¥122.30 Million ≈ $17.90 Million |
+97.83% |
| 2008-12-31 | CN¥61.82 Million ≈ $9.05 Million |
+51.89% |
| 2007-12-31 | CN¥40.70 Million ≈ $5.96 Million |
-- |
About Guanhao Biotech Co Ltd
Guanhao Biotech Co.,Ltd. develops, manufactures, and sells regenerative medicines and life sciences products in China. It offers NormalGEN and GrandNeuro, both a dura repair patch; ThormalGEN, a surgical patch; DermalGEN, a wound dressing product; IREAL breast patch; and Youvision corneal graft, as well as license in intraocular lenses. The company also provides Biological dura, a spinal patch; T… Read more